Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 19/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623759 | 0.86 | DDB1 (1.00) | DDB1CRBNSMN1; SMN2 | |
| SCHEMBL22612123 | 0.85 | DDB1 (1.00) | DDB1CRBNSMN1; SMN2 | |
| SCHEMBL25905402 | 0.77 | DDB1 (0.70) | DDB1CRBNSMN1; SMN2 | |
| SCHEMBL22623669 | 0.75 | DDB1 (1.00) | DDB1CRBNSMN1; SMN2 | |
| SCHEMBL22612089 | 0.75 | DDB1 (1.00) | DDB1CRBN | |
| SCHEMBL2790063 | 0.73 | SMN1; SMN2 (1.00) | DDB1CRBNSMN1; SMN2 | |
| SCHEMBL22623731 | 0.72 | CRBN (1.00) | DDB1CRBN | |
| SCHEMBL9571741 | 0.71 | DDB1 (0.53) | DDB1CRBNSMN1; SMN2 | |
| SCHEMBL22612114 | 0.70 | CRBN (1.00) | DDB1CRBN | |
| SCHEMBL22623705 | 0.70 | DDB1 (0.64) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885SMN1; SMN2 701/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885SMN1; SMN2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.